If your chronic inflammatory demyelinating polyneuropathy (CIDP) treatment has hit a plateau, new options like FcRn inhibitors and B-cell therapies may help.

For people living with primary immunodeficiency (PI), immunoglobulin replacement therapy (Ig) is a cornerstone of treatment. It helps prevent serious infections, reduces hospitalizations, and supports ...

Background: Muscle-specific kinase (MuSK) myasthenia gravis is a rare autoimmune disorder of the neuromuscular junction that predominantly affects the bulbar and respiratory muscles. Although SARS-CoV ...

In a new trial, the Bruton tyrosine kinase (BTK) inhibitor pirtobrutinib increased the rate of survival without disease progression and was well tolerated with a more favorable safety profile when ...

In a trial, rituximab demonstrated clinical efficacy in reducing proteinuria in patients with FRNS or SDNS. Intravenous rituximab is safe and effective in patients with frequently relapsing nephrotic ...

ABSTRACT: In hypersensitized patients, Kidney Transplant (KT) rates are low due to the risk of organ loss due to rejection. Desensitization (DS) protocols have been developed to prevent rejection, ...

Intravenous immunoglobulin (IVIG) therapy involves infusing patients with naturally occurring IgG antibodies to treat autoimmune conditions. With origins dating back to the 1950s, IVIG is currently ...

Primary nephrotic syndrome in adults is characterized by severe proteinuria and hypoalbuminemia. This was the first clinical trial to test rituximab in adult-onset frequently relapsing nephrotic ...

One monoclonal antibody, rituximab, can work wonders for the treatment of children with frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome. However, what about patients ...

Hyperhemolysis syndrome (HHS) is a rare but severe complication of red blood cell transfusion, characterized by the destruction of both the patient’s and donor’s red blood cells. This condition ...